VOR
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Vor Biopharma Inc. (VOR) is rated C+ (2.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (B+); its weakest is Profitability (D-). The rating has held at C+ for 5 weeks.
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-11-15 | B+ (3.8) | C+ (2.7) | D- (0.9) | B (3.2) | C+ (2.6) | C+ (2.7) |
| 2026-11-08 | B+ (3.8) | C+ (2.7) | D- (0.9) | C+ (2.8) | C+ (2.6) | C+ (2.6) |
| 2026-11-01 | A- (3.9) | C+ (2.6) | D- (0.8) | B- (3.0) | C+ (2.7) | C+ (2.6) |
| 2026-10-25 | B+ (3.8) | C+ (2.6) | D- (0.9) | B- (2.9) | C+ (2.6) | C+ (2.6) |
| 2026-10-18 | B+ (3.7) | C+ (2.5) | D- (0.9) | B- (3.1) | C+ (2.6) | C+ (2.6) |